SNX-5422 Uses, Dosage, Side Effects and more

SNX-5422 is a synthetic, novel, small molecule Hsp90 Inhibitor. As an oral formulation that demonstrates strong efficacy and tolerability, SNX-5422 is positioned as a breakthrough therapy with broad applicability across a wide range of cancers.

SNX-5422 is under development by Serenex. It is orally administered (pill form). Once in the body, SNX-5422 is converted to SNX-2122; that is, SNX-5422 is a prodrug of SNX-2112, which is the active form.

Trade Name SNX-5422
Generic SNX-5422
Type
Formula C25H30F3N5O4
Weight Average: 521.541
Monoisotopic: 521.224988955
Groups Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated: January 7, 2025 at 1:49 am

Uses

Investigated for use/treatment in cancer/tumors (unspecified).

How SNX-5422 works

SNX-5422 is a direct, potent inhibitor of Hsp90 across a broad range of human cancer cell lines and causes degradation of important Hsp90 client proteins including HER2, AKT and ERK.

Innovators Monograph

*** Taking medicines without doctor's advice can cause long-term problems.
Share